Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Black Diamond Therapeutics, Inc. BDTX
$1.90
-$0.02 (-1.04%)
На 18:02, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
63883400.00000000
-
week52high
4.08
-
week52low
1.18
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.87970700
-
EPS
-2.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Neutral | Outperform | 29 мар 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 22 мар 2022 г. |
| Stifel | Hold | Hold | 18 мар 2022 г. |
| Stifel | Hold | 30 сент 2021 г. | |
| Wedbush | Outperform | 07 янв 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ni Fang | A | 125389 | 36363 | 22 дек 2022 г. |
| Ni Fang | A | 89026 | 20000 | 21 дек 2022 г. |
| Behbahani Ali | A | 28004 | 7917 | 16 дек 2022 г. |
| INGRAM ROBERT ALEXANDER | A | 42854 | 9375 | 16 дек 2022 г. |
| DIXON WENDY L | A | 16216 | 7167 | 16 дек 2022 г. |
| Velleca Mark A. | A | 21157 | 8424 | 16 дек 2022 г. |
| BIOTECH GROWTH N V | A | 5377839 | 99801 | 31 окт 2022 г. |
| BIOTECH GROWTH N V | A | 5278038 | 172974 | 28 окт 2022 г. |
| BIOTECH GROWTH N V | A | 5105064 | 191678 | 27 окт 2022 г. |
| BIOTECH GROWTH N V | A | 4913386 | 87850 | 21 окт 2022 г. |
Новостная лента
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
05 янв 2023 г. в 08:00
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company's progress at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California.
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
Zacks Investment Research
09 дек 2022 г. в 11:17
Black Diamond (BDTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
09 ноя 2022 г. в 08:00
CAMBRIDGE, Mass. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that company management will participate in three upcoming investor conferences:
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
06 сент 2022 г. в 08:00
CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company's progress at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available for on-demand viewing beginning Monday, September 12, 2022, starting at 7:00 AM ET.
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
GlobeNewsWire
03 авг 2022 г. в 08:00
CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will participate in a panel discussion titled, Bullseye - Targeted Oncology - Quanta of Targets, at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 10:20 a.m. ET.